Learn about funding opportunities for research institutions, hospitals, companies (SMEs) and other stakeholders in the area of medicine and therapeutic development.
The Innovative Medicines Initiative (IMI) www.imi.europa.eu  is Europe’s largest public-private partnership in life science. It is jointly run and funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Its aim is to improve the process of developing new medicines and treatments by supporting cooperation in research and development.
Launched in 2008, the initiative is now being renewed under the EU’s framework programme Horizon 2020. IMI2 will run for 10 years with a budget of approximately €3 billion euro. The IMI2 Information and Networking Meeting in Oslo is an opportunity for a wide range of stakeholders to learn about the research priorities of IMI2 and the calls to be launched in 2014 and 2015. The event will also highlight the experiences and learnings of Swedish and Norwegian IMI project participants and how to engage and partner in future calls and project consortia.
The event is organized by The Research Council of Norway (RCN) and VINNOVA, the Swedish innovation agency.